Quantcast

Latest Organofluorides Stories

2014-07-28 04:21:34

HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data from plasma samples to guide the use of IRESSA for non-small cell lung cancer patients - New blood test will build on QIAGEN's FDA-approved therascreen EGFR test and is planned to run on Rotor-Gene Q, member of the QIAsymphony family of automated instruments -...

2014-07-27 23:01:51

The Firm is currently representing clients in Risperdal lawsuits that similarly allege the atypical antipsychotic medication caused gynecomastia, a condition categorized by male breast development. New York, NY (PRWEB) July 27, 2014 A consolidated litigation that now includes more than 600 Risperdal lawsuit (http://www.lawreward.com/risperdal/) filings is proceeding in the Philadelphia Court of Common Pleas, where a meeting has been scheduled in August to discuss claims involving the...

2014-07-25 04:21:37

WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., July 25, 2014 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR(®) (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). The study, called RESILIENCE, evaluated the efficacy and safety of sorafenib in combination with capecitabine, an...

2014-07-23 23:16:39

The Firm is representing numerous clients in Risperdal lawsuits who allegedly developed gynecomastia, or male breast growth, due to their use of the atypical antipsychotic medication. New York, NY (PRWEB) July 22, 2014 The Pennsylvania judge overseeing hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) in the Philadelphia Court of Common Pleas won’t reconsider his decision to deny punitive damages in cases alleging the medication caused plaintiffs to develop...

2014-07-22 08:32:36

Additional Independent Review Board Approvals Expected for Phase 2 Trial (Study 202) SAN DIEGO, July 22, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant...

2014-07-17 16:26:09

NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use small molecules as the active component. The company has a partnership with Roche to commercialize, market and distribute cobi. Cobi is expected to earn approval in the treatment of melanoma by late 2015, after positive phase-three trial results earlier this week. Cabo is...

2014-07-16 23:03:02

North America is a dominant market for PVDF owing to significant demand from the U.S. and the growing wire and cable market where PVDF are used as jacketing material and primary insulation material. http://www.micromarketmonitor.com/market/north-america-polyvinylidene-fluoride-pvdf-3151454354.html (PRWEB) July 16, 2014 Polyvinylidene fluoride, or polyvinylidene difluoride (PVDF) is a highly non-reactive and pure thermoplastic fluoropolymer produced by the polymerization of vinylidene...

2014-07-15 08:28:28

Eighty Percent of Patients Treated with G-202 had No Tumor Growth at Two Months SAN ANTONIO, July 15, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation. Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC) patients, presented the HCC clinical trial update for G-202 at the 5(th) Asia-Pacific Primary Liver...

2014-07-14 08:26:29

Submission based on first head-to-head study vs. oral treatments in real world context TITUSVILLE, N.J., July 14, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking a label change that, if approved, would include new data showing significantly delayed time to relapse in patients prescribed once-monthly atypical long-acting antipsychotic INVEGA(®)...

2014-07-13 23:03:21

As Lipitor Lawsuits Await Litigation The First Bellwether Trial Has Been Scheduled For July of 2015 With Depositions to Start This August Reports Wright & Schulte LLC Columbus, OH (PRWEB) July 13, 2014 Wright & Schulte LLC has learned that the first Lipitor bellwether trial has been scheduled in July of 2015, in U.S. District Court, District of South Carolina. The Lipitor lawsuits are in the discovery process in the South Carolina federal court where District Judge Richard M....


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related